
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem Inc. is showing a positive trajectory, driven by recent advancements and upcoming catalysts, particularly in their lead program's focus on the LGSOC KRAS-mt population. The company has exercised its option to license VS-7375 from GenFleet, reflecting confidence in its potential to outperform competitors in the G12D inhibitor space, with estimates suggesting peak sales could reach $250M–$300M. Additionally, the favorable safety profile of VS-7375, indicated by the absence of dose-limiting toxicities and promising preclinical efficacy data, further enhances investor optimism regarding its market potential and valuation prospects.
Bears say
Verastem Inc. has experienced volatility in its stock price, rebounding to the mid-single digits following a priority review by the FDA. However, concerns arise regarding potential dilution effects if the company raises capital at lower valuations than current estimates, which could negatively impact shareholder value. Additionally, the risk of insufficient efficacy or safety of its lead asset in clinical trials poses a significant threat to further development and could lead to substantial downward pressure on the stock price.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares